Following the completion of Phase 3 trials, MDMA-assisted therapy is currently undergoing review by the Food and Drug Administration (FDA) as a treatment for PTSD. If approved, it will be the first psychedelic treatment licensed for medical use in the United States. This presentation will explore the path that the MAPS Public Benefit Corporation (MAPS PBC) is pursuing to enable broad, equitable patient access. In some areas, MAPS PBC is deploying a “standard” pharmaceutical playbook for commercialization. However, in many others, it is innovating to address the unique challenges of MDMA-assisted therapy, including therapist education, insurance reimbursement, and more. If successful, the launch of MDMA-assisted therapy will likely spur on more innovation in the mental health care space.
